Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
The gut microbiome is no longer viewed as a mere spectator in cancer development – it is increasingly recognized as a key ...
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the ...
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...
The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results